ADA 2017

In part 2 of this Exclusive Interview, Dr. Mark Huising talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the impact of type 2 on delta cells and measuring the activity of these cells.

In part 3 of this Exclusive Interview, Dr. Mark Huising talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the impact of diabetes medications on delta cell activity.

In part 4 of this Exclusive Interview, Dr. Mark Huising explains the benefit of his research for those with diabetes, medical professionals, and medical students as well, in a conversation with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California.

In part 5, the conclusion of this Exclusive Interview, Dr. Mark Huising talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about what he's learned from colleagues and the importance of collaboration.

Dr. Sam Engel is the Associate Vice President, Cardiometabolic and Women’s Health at Merck Research Laboratories. He graduated from New York University School of Medicine. Prior to joining Merck’s team, he was a Clinical Professor at Albert Einstein College of Medicine.

Samuel Engel discusses Merck's VERTIS clinical trial program and recent ertugliflozin research including the VERTIS SITA study and the VERTIS MET study,

In this Exclusive Interview, Dr. Samuel Engel talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the results of studies related to ertugliflozin.

In part 1 of this Exclusive Interview, Dr. Samuel Engel talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the results of the new SGLT-2, ertugliflozin.

In part 2 of this Exclusive Interview, Dr. Samuel Engel explains the effects of ertugliflozin on typical biometrics in a conversation with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California.

In part 3 of this Exclusive Interview, Dr. Samuel Engel talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the cardiovascular study portion of the ertugliflozin trial.